by | Mar 9, 2022 | Alhallak, Kinan, Azab, Abdel Kareem
— Disease indication – multiple myeloma
Drug format – antibodies conjugated to nanoparticles for T-cell immunotherapy
Drug class – improved delivery platform
Research stage and Preliminary data:
In vivo:
In vitro proof of concept – in a MM cell line: NanoMuTEs and NanoTC…
by | Mar 2, 2022 | Lim, Kian-Huat, Liu, Yongjian, Zhang, Xiaohui
— Disease indication –
Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide
Drug class – First-in-class
Target – CCR2, the receptor for CCL2
Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…
by | Feb 23, 2022 | Cui, Jianmin
— Disease indication – Long QT Syndrome (resulting in ventricular arrhythmia, epilepsy, deafness)
Drug format – Small molecule
Drug class – Lead compounds are repurposed drugs
Research stage and preliminary data – Based on in silico screening of KCNQ, the researchers selecte…
by | Feb 18, 2022 | Mudd, Philip
— Technology Description
Researchers in Philip Mudd’s lab at Washington University have developed a blood biomarker test that detects impending respiratory failure before existing diagnostics. High levels of the biomarker IP-10 in the blood are correlated with the subsequent development of acu…
by | Feb 18, 2022 | Kreple, Collin, Miller, Timothy, Nielsen, Susan, Racette, Brad
— Technology Description
Researchers in Brad Racette and Tim Miller’s labs at Washington University have developed a therapeutic strategy for treating ALS by using statins to lower LDL. Statins were successful at prolonging both survival and time with a normal gait.
The researchers identif…